Erratum: Genome-wide target interactome profiling reveals a novel epigenetic pathway for oncogenic lncRNA in breast cancer.

[This corrects the article on p. 714 in vol. 9, PMID: 31105998.

Erratum: MiR-338-3p inhibits the growth and invasion of non-small cell lung cancer cells by targeting IRS2.

[This corrects the article on p. 53 in vol. 7, PMID: 28123847.

A new pH/NIR responsive theranostic agent for magnetic resonance imaging guided synergistic therapy.

New nano-reagents with diagnostic imaging and therapeutic functions are very important for precision medicine against cancer. In this work, a new nanotheraontic agent for magnetic resonance imaging (MRI) guided combined photothermal therapy (PTT) and chemotherapy was constructed based on polydopamine (PDA) functionalized copper ferrite nanospheres (PDA@CFNs). The high relaxivity makes it possible for PDA@CFNs to become a promising MRI contrast agent, providing necessary and exhaustive information for tumor diagnosis.

Type Iγ phosphatidylinositol phosphate kinase dependent cell migration and invasion are dispensable for tumor metastasis.

Type Iγ phosphatidylinositol phosphate kinase (PIPKIγ) has been associated with poor prognosis in breast cancer patients by promoting metastasis. Among the six alternative-splicing isoforms of PIPKIγ, PIPKIγ_i2 specifically targets to focal adhesions and regulates focal adhesion turnover, thus was proposed responsible for tumor metastasis. In the present study, we specifically depleted PIPKIγ_i2 from mouse triple negative breast cancer (TNBC) 4T1 cells and analyzed their behaviors.

Genome-wide target interactome profiling reveals a novel epigenetic pathway for oncogenic lncRNA in breast cancer.

Breast cancer is the most common cancer in women worldwide, accounting for approximately 500,000 deaths each year. is a highly conserved long noncoding RNA (lncRNA), and its increased expression is associated with relapse and metastatic progression in breast cancer. We performed RNA reverse transcription-associated trap sequencing (RAT-seq) to characterize the genome-wide target interaction network for and showed that interacted with multiple pathway target genes that are closely related to tumor progression and metastasis.

MicroRNA-363-3p inhibits papillary thyroid carcinoma progression by targeting PIK3CA.

MicroRNA-363-3p (miR-363-3p) reportedly plays crucial roles in tumor development and progression in many types of cancers. However, its role in papillary thyroid carcinoma (PTC) remain largely unclear. We therefore investigated the function and underlying mechanism of miR-363-3p in PTC.

MiR-338-3p inhibits the growth and invasion of non-small cell lung cancer cells by targeting IRS2.

MicroRNA-338-3p (miR-338-3p) has recently been reported to have anti-cancer efficacy in several types of cancers. However, its biological function and underlying mechanism involved in modulation of human non-small cell lung cancer (NSCLC) remain largely unknown. The present study was designed to investigate the function and underlying mechanism of miR-338-3p in human NSCLC tissues and cell lines.

MicroRNA-497 suppresses cell proliferation and induces apoptosis through targeting PBX3 in human multiple myeloma.

Aberrant expression of microRNA-497 (miRN-497) is implicated in development and progression of multiple types of cancers. However, the biological function and underlying mechanism of miR-497 in multiple myeloma (MM) remains unclear. Thus, we studied the potential biological roles of miR-497 in MM.

microRNA-141 inhibits thyroid cancer cell growth and metastasis by targeting insulin receptor substrate 2.

microRNA-141 (miR-141), a member of the miR-200 family, and has been reported to involve in tumor initiation and development in many types of cancers. However, the function and underlying molecular mechanism of miR-141 in thyroid cancer remains unclear. Therefore, the aim of this study is to identify its expression, function, and molecular mechanism in thyroid cancer.